Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty. HIMS stock is dropping. See the chart and price action here. Federal Crackdown: FDA & DOJOne catalyst for the crash was Hims’ recent aggressive attempt to launch a compounded oral semaglutide pill — a copycat of Novo Nordisk A/S’s (NYSE:NVO) newly approved oral Wegovy. The response from Washington was swift and severe:Under regulatory pressure, Hims & Hers did a U-turn on Saturday and announced it would stop o ...

Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]

Hims & Hers Health (NYSE: HIMS) stock crashed 25% through 10:45 a.m. ET Monday morning after an eventful weekend. On Thursday, the telehealth company announced it would begin selling a compounded version of Wegovy in pill form, for $49 per month. Hims & Hers doesn't manufacture "Wegovy." Novo Nordisk (NYSE: NVO) does, charging $149 per month for Wegovy (Ozempic) in pill form, and $199 injectable. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to b ...

Hims & Hers dropped its plan for a knockoff Wegovy weight-loss pill - Fast Company[Try our mini crossword with a business twist: Play Fast Company Mini Crossword]LOGIN[SUBSCRIBE]- [INNOVATION FESTIVAL]- [Video]- [Podcasts]- [Games]- [Work Life]- [Leadership]- [News]- [Design]- [Tech]- [Premium]| [Custom Studio]- [Texas A&M University]- [IBM]BY [Associated Press]Listen to this Article [More info]0:00 / 0:00[Telehealth company Hims & Hers] dropped its plan to offer a knockoff version of the [weight-loss pill ...

Quick Read Hims & Hers (HIMS) pulled its semaglutide pill after legal threats from Novo Nordisk and the FDA. Hims shares plunged 22%. Hims Q3 revenue jumped 49% to $599M despite regulatory pressure. Subscriber base expanded 21% to 2.5M users. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth compan ...

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. ...

Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.By [George Glover]ShareResize---ReprintsIn this a ...

Q4 earnings season is in full swing, as more than half of the S&P 500 companies have reported earnings results. Earnings have been a positive factor for stocks, with 79% of the 293 S&P 500 companies that have reported beating expectations. According to Bloomberg Intelligence, S&P earnings growth is expected to climb by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth. Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%.The marke ...

Morning Trade Live. Let's focus on the latest development in the weight loss drug trade. Novo Nordisk is high this morning and hims and hers is moving in the other direction quite substantially.After Hims pulled its generic wegovy pill. Both stocks have had a rough start to 2026, but today's move is a bright spot for Novo investors, so that is the focus of the morning trade. Joining us now for a closer look is Marley Kayden.Very good morning. Happy Monday Marley. So a nice shot in the arm now for Novo.It ne ...

科技七巨头多数下跌，英伟达盘中快速拉升涨超4%。高盛分析师预计，英伟达2025财年第四季度营收将达到673亿美元，同时在盈利端也将 超出市场预期；给出250美元的目标价；微软涨近2%，特斯拉小幅上涨，亚马逊、苹果则跌超1%。 甲骨文股价大涨近9.6%，创去年12月以来最大盘中涨幅。戴维森投行将其股票评级从"中性"上调至"买入"。台积电涨3%创新高，市值超1.85 万亿美元。 存储概念股走弱，美光科技跌近2.5%，闪迪跌超1.4%。英伟达或将把美光HBM4排除在Rubin架构的首年量产之外。 美东时间周一，美股三大指数涨跌不一，中概股多数下跌；英国遭遇股债汇"三杀"。 国际油价短线上扬，WTI原油、ICE布油涨幅扩大至1%，其中WTI原油突破64美元/桶。 据央视新闻报道，当地时间9日，伊朗原子能组织主席伊斯拉米就有关将浓缩铀运出伊朗的猜测表示，相关说法主要来自其他方面以及对伊 朗施压的相关势力所提出，这一议题根本不在谈判议程之中；即便个别个人或国家曾提出所谓"建议"，自认为可以提供帮助，但在正式谈判 中并未就此展开讨论。 值得注意的是，本周美国1月非农就业报告与CPI将集中发布，或将给市场研判美联储货币政策路 ...